UPDATE: Juniper to Buy Theragenics at $2.20/Share in Cash

Theragenics Corporation^® (NYSE: TGX ) (the “Company”), a medical device company serving the surgical products and prostate cancer treatment markets, announced today that it has signed a definitive merger agreement pursuant to which a newly formed affiliate (the “Purchaser”) of Juniper Investment Company, LLC will acquire all of the outstanding common stock of